MAP4K5 and melanoma: ✓a BRAFV600E inhibitor (IC50 = 31 nM); also inhibits Src-related kinase lacking C-terminal regulatory tyrosine and N-terminal myristylation sites (SRMS), activates CDC42 kinase (ACK), CRAF, MAP4K5, and Gardner-Rasheed feline sarcoma viral oncogene homology (FGR) with an IC50 value of 18, 19, 48, 51, and 63, respectively [317]✓reduces p-RPS6 (S235/235) in susceptible melanoma cells but not in resistance melanoma cells [308]✓synergistically reduces p-RPS6 (S235/235) with RICTOR-KD or S6K1/2-KD in vemurafenib-resistance melanoma cells [308]